超声联合紫杉醇微泡对卵巢癌细胞株A2780/DDP增殖和凋亡的影响

目的：探讨超声联合紫杉醇微泡对人卵巢癌细胞A2780/DDP细胞的增殖和凋亡的影响。方法：将人卵巢癌细胞株A2780/DDP随机分为5组：对照组、紫杉醇组、紫杉醇+超声组、紫杉醇微泡组和紫杉醇微泡+超声组。采用噻唑蓝（Methyl thiazolyl tetrazolium,MTT）法检测作用24、48 h和72 h后卵巢癌细胞的增殖活性,并用Hochst 33258和TUNEL染色法检测细胞凋亡情况。结果：MTT法检测显示紫杉醇微泡+超声组24、48 h和72 h抑制率分别为（37.20±2.01）%、（51.60±2.10）%和 （57.47±2.85）%,明显高于其他各处理组（P＜0.05）;Hochst 33258和TUNEL染色均显示紫杉醇微泡+超声组凋亡率最高,作用24 h后的凋亡率为(46.10±4.15)%,明显高于其余各组（P＜0.05）。结论：超声联合紫杉醇微泡能明显抑制人卵巢癌细胞A2780/DDP的增殖和诱导其凋亡。     

超声辐照携带miR-520c-3p和miR-132微泡对卵巢癌A2780/DDP细胞生物学活性影响及其机制研究

目的 探讨超声辐照携带miR-520c-3p和miR-132微泡对卵巢癌A2780/DDP细胞生物学活性影响,并进行机制研究。方法 将对数生长期的A2780/DDP细胞随机分为A组(空白对照)、B组(微泡造影剂+超声辐照)、C组(miR-520c-3p mimics+miR-132 negative control+微泡造影剂+超声辐照)、D组(miR-132 mimics+miR-520c-3p negative control+微泡造影剂+超声辐照)、E组(miR-520c-3p mimics+miR-132 mimics+微泡造影剂+超声辐照),48h后收集细胞。实时荧光定量聚合酶链式反应(RT-PCR)测定miR-520c-3p、miR-132表达水平以及磷脂酰肌醇蛋白多糖-3(GPC3)信使核糖核酸(mRNA)相对表达量,蛋白免疫印迹法测定GPC3和Hippo信号通路蛋白相对表达量。MTT法检测细胞增殖,Transwell法检测细胞迁移,Annexin V-FITC/PI双染法检测细胞凋亡。结果 与A组和B组比较,C组和E组miR-520c-3p表达水平显著上调,D组和E组m...     

过氧化氢联合低频超声波诱导卵巢癌A2780/DDP细胞凋亡的研究

目的探讨过氧化氢联合超声波诱导人卵巢癌A2780/DDP细胞凋亡的效果。方法体外培养人卵巢癌A2780/DDP细胞,MTT法研究过氧化氢对卵巢癌A2780/DDP细胞生长抑制情况,选择过氧化氢对A2780/DDP细胞作用的合适作用参数;实验分为对照组,0.5 W/cm2、30 s超声组,10μmol/L过氧化氢组,10μmol/L过氧化氢联合0.5 W/cm2、30 s超声组;不同因素作用A2780/DDP细胞24 h后,Hoechst33258染色观察细胞形态变化;流式细胞仪检测各处理因素作用A2780/DDP细胞的凋亡率;Western blot检测各组细胞caspases-9蛋白表达量的改变。结果对照组,0.5 W/cm2、30 s超声组和10μmol/L过氧化氢组无明显凋亡改变,而10μmol/L过氧化氢联合0.5 W/cm2、30 s超声组与对照组之间比较,差异具有显著性(P<0.05)。结论过氧化氢联合超声波能增强诱导人卵巢癌A2780/DDP细胞凋亡的作用。     

载多烯紫杉醇脂质微泡增强人胰腺癌BxPC3细胞的增殖抑制和凋亡诱导作用

目的制备载多烯紫杉醇脂质超声微泡,并研究其联合超声靶向微泡破裂技术(UTMD)对人胰腺癌BxPC3细胞的增殖抑制和凋亡诱导作用。方法采用机械振荡法制备载多烯紫杉醇的脂质超声微泡,检测其粒径、zeta电位、载药量、包封率等性质,MTT法检测IC50,CCK-8法检测细胞毒性作用,流式细胞术检测细胞周期,Annexin V-FITC/PI双染法检测细胞凋亡率,TUNEL法检测细胞凋亡情况,并与单纯多烯紫杉醇药物组、多烯紫杉醇药物+超声组等进行比较。结果载多烯紫杉醇超声微泡平均粒径1.6μm,微泡的包封率为64.2%,平均载药量为16.1%;载多烯紫杉醇脂质微泡组的细胞毒性作用强于其他各组(P<0.01),细胞凋亡率高于其他各组(P<0.01);载多烯紫杉醇脂质微泡组G2/M期细胞增多,与其他组比较差异有统计学意义(P<0.01)。结论载多烯紫杉醇脂质微泡联合UTMD能够增加G2/M期细胞阻滞,增强对BxPC3细胞的增殖抑制和凋亡诱导作用;载多烯紫杉醇脂质微泡有望成为一种治疗胰腺癌的新型药物载体。     

土贝母皂苷甲增强人卵巢癌A2780/DDP细胞对顺铂的敏感性

目的探讨土贝母皂苷甲(tubeimoside 1,TBMS1)促进人卵巢癌A2780/DDP细胞对顺铂(cisplatin,DDP)的增敏作用。方法采用MTT法分别检测顺铂和TBMS1对A2780/DDP细胞作用的半抑制浓度值(IC50),将实验分为对照组:只加等量生理盐水;顺铂组:给予6μmol/L顺铂处理;联合用药Ⅰ组:6μmol/L顺铂+3μmol/L TBMS1;联合用药Ⅱ组:6μmol/L顺铂+6μmol/L TBMS1。按上述方法处理细胞后,MTT法检测细胞活力;电泳法检测细胞内DNA损伤;流式细胞技术检测细胞凋亡及周期;Western blot分析周期蛋白A(Cyclin A)和周期蛋白D1(Cyclin D1)的表达。结果 TBMS1(3、6μmol/L)与顺铂(6μmol/L)联用使人卵巢癌A2780/DDP细胞对顺铂的敏感性增强;细胞的DNA损伤随TBMS1浓度的增加而明显增多;细胞周期被阻滞在S期,联合用药Ⅰ和Ⅱ组S期所占比例分别为(51.23±3.53)%、(77.34±2.80)%;细胞凋亡率为(5.19±0.78)%、(7.11±1.06)%;Cyclin A的表达为1.89±0.28及2.91±0.43,CyclinD1为0.66±0.09及0.28±0.05(P<0.05,P<0.01)。结论 TBMS1显著增加顺铂对A2780/DDP细胞增殖抑制作用,Cyclin A、Cyclin D1可能参与其调节。     

异丙酚对卵巢癌进展和顺铂敏感性的影响及机制

目的 探讨异丙酚对卵巢癌进展及顺铂(DDP)敏感性的影响及机制。方法 取对数生长期的卵巢癌细胞A2780和耐DDP卵巢癌细胞A2780/DDP,分别与异丙酚(0、1、5、10及20 mg/L)和DDP(0、5、10、20、40及80μmol/L)进行孵育,采用CCK-8法观察A2780和A2780/DDP细胞存活率;取对数生长期的A2780和A2780/DDP细胞分为Control组(等量培养基)、异丙酚组(10 mg/L异丙酚)、DDP组(10μmol/L DDP)、异丙酚+DDP组(10 mg/L异丙酚+10μmol/L DDP),克隆形成实验观察细胞克隆数,流式细胞仪检测细胞凋亡,Western blot检测凋亡蛋白B细胞淋巴瘤-XL(Bcl-xl)单克隆抗体、细胞凋亡调节因子(Bim)及活化半胱氨酸蛋白酶-3(cleaved caspase-3)表达,Transwell检测各组A2780和A2780/DDP细胞的侵袭;裸鼠移植瘤实验观察各组肿瘤生长情况。结果 A2780、A2780/DDP细胞活力随异丙酚和DDP浓度升高均下降,A2780/DDP细胞系半抑制浓度(IC_...     

LHRHa靶向紫杉醇脂质体的制备及体外抗肿瘤作用

目的:制备促黄体激素释放激素类似物(Luteinizing hormone-releasing hormone analogues,LHRHa)靶向紫杉醇脂质体(Paclitaxel liposomes,PTX-Lipo),研究其在体外增强紫杉醇(Paclitaxel,PTX)对卵巢癌A2780/DDP细胞的抑制作用。方法:采用薄膜超声法制备PTX-Lipo与LHRHa靶向紫杉醇脂质体(LHRHa-Paclitaxel liposomes,LHRHa-PTX-Lipo),用透射电镜考察脂质体形态;高效液相色谱法测定2种PTX-Lipo的包封率;激光共聚焦法通过卵巢癌A2780/DDP细胞对4-氟-7-硝基-2,1,3-苯并氧杂恶二唑荧光素的摄取检测来反映细胞对NBD-Lipo与NBD-LHRHa-Lipo的摄取情况;MTT法及细胞克隆形成实验检测LHRHa-PTX-Lipo体外对卵巢癌细胞的生长抑制情况。结果:制备LHRHa-PTX-Lipo的平均粒径123.4 nm,包封率在90%以上;A2780/DDP细胞对NBD-LHRHa-Lipo组的荧光摄取明显高于NBD-Lipo组;LHRHa-PTX-Lipo对A2780/DDP细胞的生长及克隆形成抑制明显高于PTX组及PTX-Lipo组(P<0.05)。结论:采用薄膜超声法制备的LHRHa-PTX-Lipo可使药物在靶部位聚集,增强药物对卵巢癌细胞的抑制作用。     

低剂量奥沙利铂联合紫杉醇诱导人卵巢癌细胞A2780凋亡的内质网应激机制研究

目的:本文对低剂量奥沙利铂联合紫杉醇诱导人卵巢癌细胞A2780凋亡相关机制进行研究,为新药开发和临床治疗提供参考.方法:人卵巢癌细胞A2780经低剂量奥沙利铂联合紫杉醇处理后,MTT法检测细胞增殖情况;采用real-time PCR及Western Blotting方法检测内质网应激相关蛋白PERK,CHOP以及细胞凋亡蛋白Caspase3和Caspase9的表达情况.结果:低剂量奥沙利铂(1μM)联合紫杉醇(10 mM)处理72 h后,A2780细胞抑制率为39.5％,明显高于其他组,差异具有统计学意义(P＜0.01);且PERK、CHOP及细胞凋亡蛋白在mRNA和蛋白质水平上均明显上调,差异具有统计学意义(P＜0.01).结论:低剂量奥沙利铂联合紫杉醇可能通过激活人卵巢癌细胞A2780的内质网应激及细胞凋亡通路起抑制细胞增殖的作用.     

载多烯紫杉醇脂质微泡增强人胰腺癌BxPC3细胞增殖抑制和凋亡诱导作用

制备载多烯紫杉醇脂质超声微泡,并研究其联合超声靶向微泡破裂技术（UTMD）对人胰腺癌BxPC3细胞的增殖抑制和凋亡诱导作用,为临床应用载多烯紫杉醇超声造影剂治疗胰腺癌提供理论依据。方法 采用机械振荡法制备载多烯紫杉醇的脂质超声微泡,检测其粒径、zeta电位、载药量、包封率等性质,MTT法检测IC50,CCK-8法检测细胞毒性作用,流式细胞术检测细胞周期,Annexin V-FITC/PI双染法检测细胞凋亡率,TUNEL法检测细胞凋亡情况,并与单纯多烯紫杉醇药物组、多烯紫杉醇药物+超声组等进行比较。结果 载多烯紫杉醇超声微泡平均粒径1.6 μm,微泡的包封率为64.2%,平均载药量为16.1%;载多烯紫杉醇脂质微泡组的细胞毒性作用强于其他各组（P<0.01）,细胞凋亡率高于其他各组（P<0.01）;载多烯紫杉醇脂质微泡组G2/M期细胞增多,与其他组比较差异有统计学意义（P<0.01）。 结论 载多烯紫杉醇脂质微泡联合UTMD能够增加G2/M 期细胞阻滞,增强对BxPC3细胞的增殖抑制和凋亡诱导作用;载多烯紫杉醇脂质微泡有望成为一种治疗胰腺癌的新型药物载体。     

OSTP增强紫杉醇诱导卵巢癌A2780细胞凋亡的作用

目的 研究卵巢癌特异性结合肽（OSTP）及联合紫杉醇对卵巢癌A2780细胞生长及凋亡的影响.方法 体外培养卵巢癌A2780细胞,随机分为4组：溶剂对照组（1640和0.1％ DMSO组）、OSTP组、紫杉醇组、OSTP联合紫杉醇组.采用四甲基偶氮唑盐（MTT法）检测OSTP对A2780细胞生长的影响;用Annexin-V-FITC和PI双染法标记A2780细胞,通过流式细胞仪检测细胞凋亡情况.结果 MTT法检测OSTP以不同浓度作用于卵巢癌A2780细胞时,可对该细胞的生长起到抑制作用,与对照组相比差异有统计学意义（P＜0.01）.应用流式细胞技术检测细胞凋亡发现：不同浓度的OSTP（20、40、80、160、320μmol/L）对A2780细胞的凋亡率分别7.88％、8.348％、8.727％、9.393％和10.68％,与对照组相比差异有统计学意义（P＜0.01）,提示OSTP可诱导细胞凋亡.OSTP和紫杉醇联合应用,在不同的预处理组（加OSTP80μ mol/L 0、3、6、12h）后再加紫杉醇10μmol/L作用48h,结果发现细胞凋亡率分别是39.40％、53.09％、48.18％和45.62％,均高于OSTP和紫杉醇单独用药及两者的凋亡率相加值,且差异有统计学意义（P ＜0.001）.提示OSTP能增强紫杉醇诱导的卵巢癌A2780细胞凋亡作用.结论 OSTP对卵巢癌A2780细胞有生长抑制及凋亡作用,尤其是OSTP能增强紫杉醇诱导卵巢癌A2780细胞凋亡的作用,对于探讨和开发OSTP作为靶向化疗增敏剂治疗卵巢癌有良好的应用前景.     

拓扑替康对人卵巢癌顺铂耐药细胞株作用的研究

目的:探讨拓扑替康(TPT)在体外诱导人卵巢癌顺铂耐药细胞株A2780/DDP凋亡的作用及其对凋亡相关蛋白表达的影响。方法:应用TPT诱导人卵巢癌顺铂耐药细胞株A2780/DDP凋亡,运用MTT法、透射电镜、DNA凝胶电泳检测和观察TPT对人卵巢癌顺铂耐药细胞株A2780/杀伤效应、凋亡形态、生物特性。采用Westernblot印迹杂交法以检测TPT对凋亡相关蛋白bcl-2和bax表达的影响。结果:TPT可诱导细胞株A2780/DDP凋亡,经TPT作用后A2780/DDP细胞内bax蛋白增加,而bcl-2蛋白不表达,bax/bcl-2比值增加。结论:TPT可诱导人卵巢癌顺铂耐药细胞株A2780/DDP凋亡,其机制可能与bax蛋白高表达及bax/bcl-2不表达有关。     

LHRHa靶向紫杉醇脂质体的制备及体外抗肿瘤作用

目的：制备促黄体激素释放激素类似物（Luteinizing hormone releasing hormone analogues,LHRHa)靶向紫杉醇脂质体（Paclitaxel liposomes,PTX-Lipo）,研究其在体外增强紫杉醇（Paclitaxel,PTX）对卵巢癌A2780/DDP细胞的抑制作用。方法：采用薄膜超声法制备PTX-Lipo与LHRHa靶向紫杉醇脂质体（LHRHa-Paclitaxel liposomes,LHRHa-PTX-Lipo）,用透射电镜考察脂质体形态;高效液相色谱法测定2种PTX-Lipo的包封率;激光共聚焦法通过卵巢癌A2780/DDP细胞对4-氟-7-硝基-2,1,3-苯并氧杂恶二唑荧光素的摄取检测来反映细胞对NBD-Lipo与NBD-LHRHa-Lipo的摄取情况;MTT法及细胞克隆形成实验检测LHRHa-PTX-Lipo体外对卵巢癌细胞的生长抑制情况。-结果：制备LHRHa-PTX-Lipo的平均粒径123.4 nm,包封率在90%以上;A2780/DDP细胞对NBD-LHRHa-Lipo组的荧光摄取明显高于NBD-Lipo组;LHRHa-PTX-Lipo对A2780/DDP细胞的生长及克隆形成抑制明显高于PTX组及PTX-Lipo组（P＜0.05）。结论：采用薄膜超声法制备的LHRHa-PTX-Lipo可使药物在靶部位聚集,增强药物对卵巢癌细胞的抑制作用。     

The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells

Summary To investigate the relationship between p38 mitogen-activated protein kinase (p38MAPK) and cell apoptosis during the paclitaxel resistance of ovarian carcinoma cell lines, flow cytometry (FCM) and PI staining were employed to determine the effect of p38MAPK inhibitor SB203580 on the apoptosis of A2780/Taxol cells, a drug-resistant human ovarian carcinoma cell line. p38MAPK protein expression in SB203580-treated cells was immunochemically measured. The 50% inhibition concentration (IC₅₀) of paclitaxel on A2780/Taxol cells was determined by MTT assay. MDR-1 mRNA, and expression of p38MAPK and phospho-p53 protein were detected by RT-PCR and Western blotting, respectively. The apoptosis rate of A2780/Taxol cells was (19.7±1.04)% 24 h after SB203580 treatment. A significant difference in apoptosis rate was found among experiment group, control group and untreated group (P<0.05). The relative reversal rate of A2780/Taxol cells to paclitaxel was (57.18±2.01)%. As compared with the control group and the untreated group, p38MAPK protein and MDR-1 mRNA in SB203580-treated cells was substantially decreased. The expression of p53 protein was significantly increased. It is concluded that p38MAPK pathway is related to paclitaxel resistance of ovarian carcinoma, and blockade of this pathway can promote the apoptosis of the drug-resistant cells and reverse the drug-resistance. Moreover, p38MAPK-mediated apoptosis in paclitaxel-resistant ovarian carcinoma cells depends on the activation of p53. This project was supported by a grant from R&D program of Heilongjiang Province (No. GB05C402-11).     

外源性表达VEGF165b对顺铂诱导人膀胱癌T24细胞损伤的影响及其机制

目的:观察人膀胱癌T24细胞中外源性表达血管内皮生长因子(VEGF)变构体VEGF165b对顺铂(DDP)诱导人膀胱癌T24细胞损伤的作用,并探讨相关机制。方法:构建VEGF165b表达载体pcDNA-VEGF165b;T24细胞分为对照组、VEGF165b组(转染VEGF165b表达载体)、DDP组和VEGF165b+DDP组(DDP联合转染VEGF165b表达载体)。MTT法检测各组细胞存活率;Western blotting法检测各组T24细胞中凋亡相关蛋白Bcl-2、Bax和caspase3表达;TUNEL法检测细胞凋亡数。结果:MTT法检测,与对照组比较, VEGF165b组24和48 h时T24细胞存活率无明显变化(P>0.05);与DDP组比较,VEGF165b+DDP组24和48 h时细胞存活率均明显降低(P<0.05)。Western blotting法检测,与对照组比较,DDP组细胞中cleaved-caspase3/pro-caspase3比值升高(P<0.05),Bcl-2/Bax比值降低(P<0.05);与DDP组比较,VEGF165b+DDP组细胞中cleaved-caspase3/pro-caspase3比值升高(P<0.05),Bcl-2/Bax比值降低(P<0.05)。TUNEL法检测,与对照组(5.1±2.7)和VEGF165b组(7.4±3.2)比较,DDP组的凋亡细胞数(26.3±8.2)的凋亡细胞数增加(P<0.05)。与DDP组比较,VEGF165b+DDP组的凋亡细胞数(41.3±6.9)增加(P<0.05)。结论:外源性表达VEGF165b能通过增加细胞凋亡促进DDP对T24细胞的损伤,其机制与VEGF信号通路受抑制有关联。     

葡萄籽原花青素对人卵巢癌耐药细胞COC1/DDP在体外的增殖抑制作用

目的 观察葡萄籽来源的原花青素(grape seed proanthoeyanidin extract,GSPE)对人卵巢癌耐药细胞COC1/DDP在体外的增殖抑制作用,并初步探讨其作用机制.方法 以MTT法检测不同浓度的GSPE(0、20、40、80、160、320μg/ml)不同时间(12、24、36、48、72 h)对COC1/DDP的增殖抑制作用,HE染色观察细胞形态变化,流式细胞仪和TUNEL检测细胞周期和凋亡,Western blot检测细胞内Caspase-3蛋白的表达.结果 GSPE对COC1/DDP具有明显的增殖抑制作用,且呈剂量-时间依赖性,不同浓度GSPE能引起细胞形态明显的凋亡改变.流式细胞术和TUNEL表明GSPE可以诱导细胞凋亡,且随着药物浓度增加,凋亡率升高.Western blot检测显示随着药物浓度增加,Caspase-3蛋白表达增加.结论 原花青素可以在体外抑制人卵巢癌耐药细胞COCl/DDP的增殖并诱导其凋亡,其机制可能与上调Caspase-3蛋白表达有关.     

MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells

Summary To investigate the relationship between MDR1 and MDR3 gene and drug resistance to cisplatin of ovarian cancer cells. Two siRNAs (MDR1, MDR3) which specifically targeted MDR1 and MDR3 genes were transfered into A2780/DDP cells. Then double staining with Annexin-V-FITC/PI was used to detect cell apoptosis by the flow cytometry (FCM). A2780/DDP cell viability was determined by MTT. MDR1 and MDR3 mRNA were assessed by RT-PCR. Caspase-3 protein was detected by Western blotting. Transfection of MDR1 and MDR3 siRNA into A2780/DDP cells failed to reverse the drug-resistance of A2780/DDP cells to cisplatin (P>0.05). No significant difference in the apoptosis efficiency was observed between the MDR1 and MDR3 siRNA, pSuppressorNeo vector transfection cells and untreated cells (P>0.05). In the presence of cisplatin of different concentrations, the viability of A2780/DDP cells was not significantly decreased after the transfection. No changes in MDR1 and MDR3 mRNA were found in MDR1 and MDR3 siRNA-transfected A2780/DDP cells. As compared with pSuppressorNeo and untreated groups, no significant difference existed in the expression of MDR1 and MDR3 mRNA (P>0.05). The expression of caspase-3 protein in MDR1 and MDR3 siRNA transfected A2780/DDP cells was not significantly increased. It is concluded that multidrug resistance induced by cisplatin in ovarian carcinoma cell lines is not due to overexpression of MDR1 and MDR3 gene. The drug resistance of ovarian carcinoma cells to cisplatin is not mediated by P-glycoprotein.     

MDR1 and MDR3 Genes and Drug Resistance to Cisplatin of Ovarian Cancer Cells

To investigate the relationship between MDR1 and MDR3 gene and drug resistance to cisplatin of ovarian cancer cells. Two siRNAs (MDR1, MDR3) which specifically targeted MDR1 and MDR3 genes were transfered into A2780/DDP cells. Then double staining with Annexin- V-FITC/PI was used to detect cell apoptosis by the flow cytometry (FCM). A2780/DDP cell viability was determined by MTT. MDR1 and MDR3 mRNA were assessed by RT-PCR. Caspase-3 protein was detected by Western blotting. Transfection of MDR1 and MDR3 siRNA into A2780/DDP cells failed to reverse the drug-resistance of A2780/DDP cells to cisplatin (P>0.05). No significant differ- ence in the apoptosis efficiency was observed between the MDR1 and MDR3 siRNA, pSuppressor- Neo vector transfection cells and untreated cells (P>0.05). In the presence of cisplatin of different concentrations, the viability of A2780/DDP cells was not significantly decreased after the transfection. No changes in MDR1 and MDR3 mRNA were found in MDR1 and MDR3 siRNA-transfected A2780/DDP cells. As compared with pSuppressorNeo and untreated groups, no significant difference existed in the expression of MDR1 and MDR3 mRNA (P>0.05). The expression of caspase-3 protein in MDR1 and MDR3 siRNA transfected A2780/DDP cells was not significantly increased. It is con- cluded that multidrug resistance induced by cisplatin in ovarian carcinoma cell lines is not due to overexpression of MDR1 and MDR3 gene. The drug resistance of ovarian carcinoma cells to cisplatin is not mediated by P-glycoprotein.